Biotie reports positive top-line data from clinical study with its third generation oral PDE4 inhibitor
ELB353 is well tolerated and shows clear pharmacological activity
28-Apr-2010 -
Biotie reported that it has successfully completed a Phase I trial with its orally administered phosphodiesterase 4 (PDE4) inhibitor ELB353, intended for the treatment of chronic obstructive pulmonary disease (COPD).
The study evaluated the safety, tolerability, pharmacokinetic characteristics ...
biomarker
dosing
inhibitors
+2